Presseinformationen weltweit an Journalisten und Leser verbreiten
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth investment with 2023 CAPEX at 25% of sales Solid free cash flow at CHF 329 million Mehr
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche straight-bond issuance in line with its financing plan for 2023. The bonds have a maturity of Mehr
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 32–34% CORE EBITDA margin and double-digit ROIC Outlook 2023: higher end of mid-to-high single-digit CER sales growth and 28 to 29% Mehr
. New agreement to establish global commercial manufacturing capacity for Vaxcyte’s PCV candidates, VAX-24 and VAX-31, in adult and pediatric populations Expanded collaboration builds on Vaxcyte’s current strategy to conduct initial commercial launch of VAX-24 in adults from existing Lonza facilities Mehr
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of filling capacity will enhance Lonza’s end-to-end integrated offering for manufacturing antibody-drug conjugates (ADCs) drug substance and drug product Mehr
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation Mehr
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an overview of Lonza’s offerings, capabilities, markets and sources of competitive advantage Lonza reconfirms Outlook 2023 at mid-to-high single-digit CER sales growth Mehr
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17 confirmed Lonza announced today that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September by mutual Mehr
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying sales growth2 CHF 922 million CORE EBITDA resulted in a margin of 30% Good momentum in commercial CDMO business Group Outlook Mehr
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker Mehr